Ionis Pharmaceuticals (IONS) Stock Overview
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IONS Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.69 |
| 52 Week High | US$50.43 |
| 52 Week Low | US$23.95 |
| Beta | 0.25 |
| 1 Month Change | 1.05% |
| 3 Month Change | 28.12% |
| 1 Year Change | -8.78% |
| 3 Year Change | 1.64% |
| 5 Year Change | -21.67% |
| Change since IPO | 326.90% |
Recent News & Updates
Recent updates
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)
Aug 01
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?
Jul 30Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up
Jul 03Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight
Jun 29We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed
May 30Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates
May 02Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)
Apr 22Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way?
Apr 20Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Mar 24
Anticipated Drug Launches Will Shift Biotech Company To Commercial Stage
Ionis is set to boost revenue through first-mover advantage with TRYNGOLZA and other product launches targeting unmet medical needs.Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
Dec 23Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel
Dec 23Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 01Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
Oct 23Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Shareholder Returns
| IONS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.7% | 0.3% | 0.5% |
| 1Y | -8.8% | -7.9% | 15.9% |
Return vs Industry: IONS matched the US Biotechs industry which returned -7.9% over the past year.
Return vs Market: IONS underperformed the US Market which returned 15.9% over the past year.
Price Volatility
| IONS volatility | |
|---|---|
| IONS Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IONS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IONS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,069 | Brett Monia | www.ionis.com |
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| IONS fundamental statistics | |
|---|---|
| Market cap | US$6.80b |
| Earnings (TTM) | -US$268.22m |
| Revenue (TTM) | US$944.05m |
Is IONS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IONS income statement (TTM) | |
|---|---|
| Revenue | US$944.05m |
| Cost of Revenue | US$893.98m |
| Gross Profit | US$50.07m |
| Other Expenses | US$318.28m |
| Earnings | -US$268.22m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68 |
| Gross Margin | 5.30% |
| Net Profit Margin | -28.41% |
| Debt/Equity Ratio | 288.0% |
How did IONS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/25 14:05 |
| End of Day Share Price | 2025/08/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ionis Pharmaceuticals, Inc. is covered by 48 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| James Birchenough | Barclays |
| Huidong Wang | Barclays |